119 related articles for article (PubMed ID: 26462271)
1. VSL#3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial.
Rohatgi S; Ahuja V; Makharia GK; Rai T; Das P; Dattagupta S; Mishra V; Garg SK
BMJ Open Gastroenterol; 2015; 2(1):e000018. PubMed ID: 26462271
[TBL] [Abstract][Full Text] [Related]
2. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
[TBL] [Abstract][Full Text] [Related]
3. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis.
Sood A; Midha V; Makharia GK; Ahuja V; Singal D; Goswami P; Tandon RK
Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1202-9, 1209.e1. PubMed ID: 19631292
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases.
Chapman TM; Plosker GL; Figgitt DP
BioDrugs; 2007; 21(1):61-3. PubMed ID: 17263590
[TBL] [Abstract][Full Text] [Related]
5. Role of probiotics VSL#3 in prevention of suspected sepsis in low birthweight infants in India: a randomised controlled trial.
Sinha A; Gupta SS; Chellani H; Maliye C; Kumari V; Arya S; Garg BS; Gaur SD; Gaind R; Deotale V; Taywade M; Prasad MS; Thavraj V; Mukherjee A; Roy M
BMJ Open; 2015 Jul; 5(7):e006564. PubMed ID: 26163028
[TBL] [Abstract][Full Text] [Related]
6. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A
Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864
[TBL] [Abstract][Full Text] [Related]
7. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.
Bibiloni R; Fedorak RN; Tannock GW; Madsen KL; Gionchetti P; Campieri M; De Simone C; Sartor RB
Am J Gastroenterol; 2005 Jul; 100(7):1539-46. PubMed ID: 15984978
[TBL] [Abstract][Full Text] [Related]
8. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
Miehlke S; Madisch A; Kupcinskas L; Petrauskas D; Böhm G; Marks HJ; Neumeyer M; Nathan T; Fernández-Bañares F; Greinwald R; Mohrbacher R; Vieth M; Bonderup OK;
Gastroenterology; 2014 May; 146(5):1222-30.e1-2. PubMed ID: 24440672
[TBL] [Abstract][Full Text] [Related]
9. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease.
Fedorak RN; Feagan BG; Hotte N; Leddin D; Dieleman LA; Petrunia DM; Enns R; Bitton A; Chiba N; Paré P; Rostom A; Marshall J; Depew W; Bernstein CN; Panaccione R; Aumais G; Steinhart AH; Cockeram A; Bailey RJ; Gionchetti P; Wong C; Madsen K
Clin Gastroenterol Hepatol; 2015 May; 13(5):928-35.e2. PubMed ID: 25460016
[TBL] [Abstract][Full Text] [Related]
10. High-dose probiotics for the treatment of active pouchitis.
Gionchetti P; Rizzello F; Morselli C; Poggioli G; Tambasco R; Calabrese C; Brigidi P; Vitali B; Straforini G; Campieri M
Dis Colon Rectum; 2007 Dec; 50(12):2075-82; discussion 2082-4. PubMed ID: 17934776
[TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.
Shen B; Brzezinski A; Fazio VW; Remzi FH; Achkar JP; Bennett AE; Sherman K; Lashner BA
Aliment Pharmacol Ther; 2005 Oct; 22(8):721-8. PubMed ID: 16197493
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating.
Kim HJ; Vazquez Roque MI; Camilleri M; Stephens D; Burton DD; Baxter K; Thomforde G; Zinsmeister AR
Neurogastroenterol Motil; 2005 Oct; 17(5):687-96. PubMed ID: 16185307
[TBL] [Abstract][Full Text] [Related]
13. Effect of probiotics on nutritional status, biochemical parameters, and disease severity in cirrhotic patients referred for liver transplantation-A randomised double blind, placebo-controlled trial.
Ramachandran G; Pottakkat B; Basu S; Mohan P
Clin Nutr ESPEN; 2023 Oct; 57():703-710. PubMed ID: 37739726
[TBL] [Abstract][Full Text] [Related]
14. Effects of the probiotic formulation VSL#3 on colitis in weanling rats.
Fitzpatrick LR; Hertzog KL; Quatse AL; Koltun WA; Small JS; Vrana K
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):561-70. PubMed ID: 17460487
[TBL] [Abstract][Full Text] [Related]
15. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
[TBL] [Abstract][Full Text] [Related]
16. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
[TBL] [Abstract][Full Text] [Related]
17. Prebiotics and probiotics in irritable bowel syndrome and inflammatory bowel disease in children.
Guandalini S; Cernat E; Moscoso D
Benef Microbes; 2015; 6(2):209-17. PubMed ID: 25391345
[TBL] [Abstract][Full Text] [Related]
18. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study.
Guandalini S; Magazzù G; Chiaro A; La Balestra V; Di Nardo G; Gopalan S; Sibal A; Romano C; Canani RB; Lionetti P; Setty M
J Pediatr Gastroenterol Nutr; 2010 Jul; 51(1):24-30. PubMed ID: 20453678
[TBL] [Abstract][Full Text] [Related]
19. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis.
Ardizzone S; Maconi G; Russo A; Imbesi V; Colombo E; Bianchi Porro G
Gut; 2006 Jan; 55(1):47-53. PubMed ID: 15972298
[TBL] [Abstract][Full Text] [Related]
20. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
